- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 84
- States / cities
- Gulf Shores, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 81 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil and olmesartan, Olmesartan, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more
- Conditions
- Hypertension
- Interventions
- Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 86
- States / cities
- Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Essential Hypertension
- Interventions
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,085 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
- Conditions
- Heart Failure, Systolic, Frailty
- Interventions
- sacubitril/valsartan, Angiotensin II Receptor Blockers
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 40,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension
- Interventions
- Azilsartan Medoxomil, Olmesartan, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 46
- States / cities
- Huntsville, Alabama • Ozark, Alabama • Mesa, Arizona + 43 more